Stayble Therapeutics AB (DE:4K4)
FRANKFURT:4K4
Want to see DE:4K4 full AI Analyst Report?
4K4 Stock Chart & Stats
€0.02
>-€0.01(-2.27%)
At close: 4:00 PM EST
€0.02
>-€0.01(-2.27%)
Day’s Range― - ―
52-Week Range€0.01 - €0.05
Previous CloseN/A
Volume0.00
Average Volume (3M)0.00
Market Cap
€232.82K
Enterprise Value€469.94K
Total Cash (Recent Filing)€2.45M
Total Debt (Recent Filing)€0.00
Price to Earnings (P/E)―
Beta0.25
Next EarningsN/A
EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)N/A
Shares Outstanding64,359,795
10 Day Avg. Volume0
30 Day Avg. Volume0
Financial Highlights & Ratios
PEG Ratio0.03
Price to Book (P/B)1.92
Price to Sales (P/S)0.00
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Focused Clinical-stage PipelineA focused, clinical-stage lead asset (STA363) gives the company a clear scientific and regulatory path to create value. For a biotech, concentrating resources on one prioritized program can accelerate milestone-driven value creation and simplify capital allocation decisions over months.
Very Low Financial LeverageMinimal debt reduces fixed financial obligations and interest risk, preserving flexibility to fund clinical development through equity or partnerships. This structural low-leverage profile lowers bankruptcy risk and eases balance-sheet management during multi-stage R&D programs.
Improving Operating Cash BurnA materially improving operating cash outflow trend reflects cost control or streamlined operations. Sustained reduction in burn rate lengthens runway per financing round, reducing near-term dilution risk and increasing the odds management can reach next clinical inflection points before raising capital.
Bears Say
No Revenue GenerationAbsence of any revenue confirms a pure R&D-stage biotech model; value therefore depends entirely on future clinical success and external funding. This structural lack of operating income implies prolonged reliance on capital markets and milestone-dependent valuation.
Sharply Eroded Equity And AssetsSignificant decline in equity and assets weakens the balance sheet's shock absorption and limits non-dilutive financing options. Persistent losses reducing book value increase the probability of future equity raises and potential dilution, materially affecting long-term shareholder value.
Negative Cash Flow, Funding DependenceConsistent negative operating cash flows and negative free cash flow across years create structural liquidity risk. The company must access external capital or partnerships to progress trials, which can be dilutive and contingent on market conditions and clinical readouts.
4K4 FAQ
What was Stayble Therapeutics AB’s price range in the past 12 months?
Stayble Therapeutics AB lowest stock price was €0.01 and its highest was €0.05 in the past 12 months.
What is Stayble Therapeutics AB’s market cap?
Stayble Therapeutics AB’s market cap is €232.82K.
When is Stayble Therapeutics AB’s upcoming earnings report date?
The company’s upcoming earnings report date is not yet available.
How were Stayble Therapeutics AB’s earnings last quarter?
Currently, no data Available
Is Stayble Therapeutics AB overvalued?
According to Wall Street analysts Stayble Therapeutics AB’s price is currently Overvalued.
Does Stayble Therapeutics AB pay dividends?
Stayble Therapeutics AB does not currently pay dividends.
What is Stayble Therapeutics AB’s EPS estimate?
Stayble Therapeutics AB’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Stayble Therapeutics AB have?
Stayble Therapeutics AB has 64,359,795 shares outstanding.
What happened to Stayble Therapeutics AB’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of Stayble Therapeutics AB?
Currently, no hedge funds are holding shares in DE:4K4
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Stayble Therapeutics AB
Stayble Therapeutics AB (publ) develops injectable treatment for chronic low back pain triggered by disc degeneration. The company develops STA363, a minimally invasive single injection of the drug into the disc that targets chronic low back pain. Stayble Therapeutics AB (publ) was incorporated in 2015 and is based in Gothenburg, Sweden.